243 related articles for article (PubMed ID: 19384695)
1. Some notable properties of the standard oncology Phase I design.
Hather GJ; Mackey H
J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
[TBL] [Abstract][Full Text] [Related]
2. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
3. Dose-escalation designs in oncology: ADEPT and the CRM.
Shu J; O'Quigley J
Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
[TBL] [Abstract][Full Text] [Related]
4. New adaptive method for phase I trials in oncology.
Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
[TBL] [Abstract][Full Text] [Related]
5. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
Seegers V; Chevret S; Resche-Rigon M
Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
[TBL] [Abstract][Full Text] [Related]
7. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
8. Designs for single- or multiple-agent phase I trials.
Conaway MR; Dunbar S; Peddada SD
Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
10. Design issues in dose-finding Phase I trials for combinations of two agents.
Fan SK; Venook AP; Lu Y
J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian dose finding design for dual endpoint phase I trials.
Loke YC; Tan SB; Cai Y; Machin D
Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
[TBL] [Abstract][Full Text] [Related]
12. [Continual reassessment method (CRM)].
Ishizuka N
Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
[TBL] [Abstract][Full Text] [Related]
13. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
Ivanova A; Wang K
Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
[TBL] [Abstract][Full Text] [Related]
14. Small-sample behavior of novel phase I cancer trial designs.
Oron AP; Hoff PD
Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
[TBL] [Abstract][Full Text] [Related]
15. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
16. Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.
Lee SM; Wages NA; Goodman KA; Lockhart AC
JCO Precis Oncol; 2021 Jan; 5():317-324. PubMed ID: 34151131
[TBL] [Abstract][Full Text] [Related]
17. An optimization algorithm for designing phase I cancer clinical trials.
Jiang H; Liu Y; Su Z
Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
[TBL] [Abstract][Full Text] [Related]
18. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
19. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
Potter DM
J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
[TBL] [Abstract][Full Text] [Related]
20. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
